We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Calliditas' (CALT) Tarpeyo Wins FDA Approval for Renal Disease
Read MoreHide Full Article
Calliditas Therapeutics AB (CALT - Free Report) announced that the FDA has approved Tarpeyo delayed-release capsules.
The drug has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g.
Tarpeyo is approved under accelerated approval based on achieving its primary endpoint of reduction in proteinuria in Part A of the NeflgArdn study.
The global clinical study, NeflgArd, is an ongoing phase III randomized, double-blind, placebo- controlled, multicenter study to evaluate the efficacy and safety of Tarpeyo 16 mg once daily versus placebo in adult patients with primary IgAN as an addition to optimized RASi therapy. Patients taking Tarpeyo (n=97) showed a statistically significant 34% reduction in proteinuria from baseline versus 5% with RASi alone (n=102) in nine months.
Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical study.
Primary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger's Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when galactose-deficient IgA1 are recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular mesangium of the kidney. The disease has a high unmet need, with more than 50% of patients potentially progressing to end-stage renal disease (ESRD).
Shares are up 39% in after-market trading hours. However, the stock plunged 44.6% in the year compared with the industry’s 19% decline.
Image Source: Zacks Investment Research
This is the first approved product in the company’s portfolio and the successful commercialization of the drug will boost prospects.
Chinook Therapeutics, Inc. is evaluating atrasentan, a phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. The European Commission recently granted orphan drug designation to Chinook’s atrasentan to treat primary IgAN.
BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase Ib trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases.
Estimates for Sarepta have narrowed from a loss per share of $6.95 to $4.99 for 2021 and from $4.78 to $3.61 for 2022 in the past 60 days. SRPT delivered an earnings surprise of 11.06%, on average, in the last four quarters.
Estimates for Viking Therapeutics have narrowed to a loss per share of $3.16 from $3.55 for 2021 and to $3.47 from $3.63 for 2022 in the past 60 days. VKTX delivered an earnings surprise of 2.06%, on average, in the last four quarters.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Calliditas' (CALT) Tarpeyo Wins FDA Approval for Renal Disease
Calliditas Therapeutics AB (CALT - Free Report) announced that the FDA has approved Tarpeyo delayed-release capsules.
The drug has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g.
Tarpeyo is approved under accelerated approval based on achieving its primary endpoint of reduction in proteinuria in Part A of the NeflgArdn study.
The global clinical study, NeflgArd, is an ongoing phase III randomized, double-blind, placebo- controlled, multicenter study to evaluate the efficacy and safety of Tarpeyo 16 mg once daily versus placebo in adult patients with primary IgAN as an addition to optimized RASi therapy. Patients taking Tarpeyo (n=97) showed a statistically significant 34% reduction in proteinuria from baseline versus 5% with RASi alone (n=102) in nine months.
Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical study.
Primary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger's Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when galactose-deficient IgA1 are recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular mesangium of the kidney. The disease has a high unmet need, with more than 50% of patients potentially progressing to end-stage renal disease (ESRD).
Shares are up 39% in after-market trading hours. However, the stock plunged 44.6% in the year compared with the industry’s 19% decline.
This is the first approved product in the company’s portfolio and the successful commercialization of the drug will boost prospects.
Chinook Therapeutics, Inc. is evaluating atrasentan, a phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. The European Commission recently granted orphan drug designation to Chinook’s atrasentan to treat primary IgAN.
BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase Ib trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases.
Calliditas currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector are Sarepta Therapeutics, Inc. (SRPT - Free Report) and Viking Therapeutics (VKTX - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Sarepta have narrowed from a loss per share of $6.95 to $4.99 for 2021 and from $4.78 to $3.61 for 2022 in the past 60 days. SRPT delivered an earnings surprise of 11.06%, on average, in the last four quarters.
Estimates for Viking Therapeutics have narrowed to a loss per share of $3.16 from $3.55 for 2021 and to $3.47 from $3.63 for 2022 in the past 60 days. VKTX delivered an earnings surprise of 2.06%, on average, in the last four quarters.